HemaSphere (Aug 2023)
S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
Abstract
No abstracts available.
HemaSphere (Aug 2023)